Drug Information

Drug General Information
Drug ID
D0Y5ED
Former ID
DIB015617
Drug Name
AV-203
Synonyms
ErbB3-targeted antibodies (cancer), AVEO/Biogen Idec
Drug Type
Antibody
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 1 [523911]
Company
Aveo oncology
Target and Pathway
Target(s) Receptor protein-tyrosine kinase erbB-3 Target Info [533093]
KEGG Pathway ErbB signaling pathway
Calcium signaling pathway
Endocytosis
Proteoglycans in cancer
MicroRNAs in cancer
NetPath Pathway TNFalpha Signaling Pathway
PANTHER Pathway Cadherin signaling pathway
EGF receptor signaling pathway
Pathway Interaction Database ErbB2/ErbB3 signaling events
ErbB receptor signaling network
a6b1 and a6b4 Integrin signaling
WikiPathways ErbB Signaling Pathway
Apoptosis-related network due to altered Notch3 in ovarian cancer
Signaling Pathways in Glioblastoma
miR-targeted genes in muscle cell - TarBase
Heart Development
References
Ref 523911ClinicalTrials.gov (NCT01603979) A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 533093Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models. Clin Cancer Res. 2015 Mar 1;21(5):1106-14.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.